Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) - CAPItello280

Study identifier:D361EC00001

ClinicalTrials.gov identifier:NCT05348577

EudraCT identifier:2021-005201-27

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

Medical condition

prostate cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

capivasertib, docetaxel

Sex

Male

Actual Enrollment

1017

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Mar 2022
Estimated Primary Completion Date: 21 Dec 2026
Estimated Study Completion Date: 21 Dec 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria